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Background: The clinical efficacy and safety of doxycycline hyclate (8.5% w/w) delivered subgingivally in a
biodegradable polymer (DH) was compared to placebo control (VC), oral hygiene (OH), and scaling and root
planing (SRP) in 2 multi-center studies.
Methods: Each study entered 411 patients who demonstrated moderate to severe periodontitis. Patients had 2
or more quadrants each with a minimum of 4 qualifying pockets ≥5 mm that bled on probing. At least 2 of the
pockets were ≥7 mm. Treatment with DH, VC, OH, or SRP was provided at baseline and again at month 4. Clinical
parameters were recorded monthly.
Results: DH and SRP resulted in nearly identical clinical changes over time in both studies. Mean 9 month clini-
cal attachment level gain (ALG) was 0.8 mm for the DH group and 0.7 mm for the SRP group in Study 1, and
0.8 mm (DH) and 0.9 mm (SRP) in Study 2. Mean probing depth (PD) reduction was 1.1 mm for the DH group
and 0.9 mm for the SRP group in Study 1 and 1.3 mm for both groups in Study 2. Frequency distributions showed
an ALG ≥2 mm in 29% of DH sites versus 27% of SRP sites in Study 1 and 31% of DH sites versus 34% of SRP sites
in Study 2. PD reductions ≥2 mm were seen in 32% of DH sites versus 31% of SRP sites in Study 1 and 41% of DH
sites versus 43% of SRP sites in Study 2. Comparisons between DH, VC, and OH treatment groups showed DH
treatment to be statistically superior to VC and OH. Safety data demonstrated a benign safety profile with use of
the DH product.
Conclusions: Results of this trial demonstrate that treatment of periodontitis with subgingivally delivered doxy-
cycline in a biodegradable polymer is equally effective as scaling and root planing and superior in effect to placebo
control and oral hygiene in reducing the clinical signs of adult periodontitis over a 9-month period. This represents
positive changes resulting from the use of subgingivally applied doxycycline as scaling and root planing was not
limited regarding time of the procedure or use of local anesthesia. J Periodontol 1999;70:490-503.
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T
he elimination or alteration of the microbial
pathogens present in subgingival plaque is the
primary object of periodontal therapy.
Complications from the inflammatory lesion resulting
from this infection lead to progressive destruction of the
supporting periodontal attachment apparatus in sus-
ceptible hosts. The microbial factors1 associated with
periodontal diseases, as well as their pathogenesis,2
have been recently reviewed. One essential goal of cur-
rent periodontitis therapy is successful management of
the suspected bacterial pathogens to the extent that
destruction of the periodontium is arrested. A number
of different non-surgical and surgical therapies have
been successful in achieving this goal.3-6 The primary
non-surgical approach involves mechanical scaling and
root planing (SRP).3
Another less invasive approach is to control the sus-
pected bacterial pathogens by administering an antimi-
crobial agent into the periodontal pocket. With this type
of treatment, delivery systems that are biodegradable
and provide controlled release of the antimicrobial
agent seem ideal. They provide appropriate antimicro-
bial levels for sustained periods without frequent applica-
tions or need for removal at some future timepoint.7-9
Many different delivery systems containing various
antimicrobial agents have been, and are being, devel-
oped as non-mechanical therapies for periodontitis.
They are used either adjunctively or independently of
mechanical treatments as monotherapy.10
The 2 studies reported in this paper were designed to
test the safety and effectiveness of doxycycline hyclate
delivered subgingivally to human periodontal pockets
in a biodegradable controlled-release delivery system.
Animal results11 and a large multi-center human clini-
cal trial12 have shown favorable responses following
use of this treatment for periodontitis. The studies
reported in this paper are the basis for the clinical por-
tion of a New Drug Application with the U.S. Food and
Drug Administration for acceptance of this product to
treat human periodontitis. 
MATERIALS AND METHODS
Study Design
These two 9-month, multi-center studies used random-
ized, parallel, single-blind designs and compared results
of 1) subgingivally administered doxycycline hyclate
(DH); 2) vehicle control (VC); 3) oral hygiene (OH);
and 4) scaling and root planing (SRP). In each study
(10 research centers per study; 6 to 15 subjects per
group at each center), 411 patients were entered of
whom 375 completed Study 1 and 383 Study 2.
Subjects were excluded from participation in the study
if they were using any contraindicated medications,
presented with compromising medical conditions, or
had been treated with SRP within 2 months of the base-
line treatment visit. The elements of the studies have
been discussed in detail in a previous research report.13
Both were carried out in an identical manner and were
conducted in compliance with FDA Good Clinical
Practice Guidelines, institutional review board (IRB)
requirements,14 and informed consent requirements.15
The protocols and informed consent were approved by
the appropriate human subjects review committees and
reviewed by the FDA. A brief summary of the study
design is provided below.
Subject Eligibility
Eligibility was determined at a screening examination.
Subjects were included if they gave informed consent,
were 25 to 75 years of age, and had generalized mod-
erate to severe periodontitis in at least 2 quadrants. To
qualify, each of the 2 quadrants had to contain a mini-
mum of 4 periodontal pocket sites ≥5 mm that bled on
probing. Two of the qualifying sites were required to
have a probing depth ≥7 mm. Other details of the
exclusion/inclusion criteria have been published previ-
ously.13 Each subject was randomized to 1 of 4 treat-
ment groups: 1) doxycycline hyclate (DH); 2) vehicle
control (VC); 3) oral hygiene (OH); and 4) scaling and
root planing (SRP). Each subject received only one
treatment in this parallel design study.
Treatment Procedures
The formulation containing doxycycline hyclate (DH)
was a solution containing 8.5% weight to weight doxy-
cycline hyclate, 37% weight to weight poly(DL-lactide)
(PLA) dissolved in a biocompatible carrier of 63%
weight to weight N-methyl-2-pyrrolidone (NMP).†††† In
the case of DH, the 2 components of the formulation
(vehicle and doxycycline hyclate) were provided in 2
separate syringes that were coupled together just prior
to use and mixed for 100 cycles. Once mixed, the DH
was allowed to sit at room temperature for 15 minutes
and then mixed for another 10 cycles before use. A 23-
gauge cannula was attached to the delivery syringe and
the DH was expressed into the periodontal pocket. Any
overflow material was gently packed into the pocket
with a moist curet. Qualifying sites in 2 quadrants were
treated.
The vehicle control (VC) was a solution containing
37% weight to weight PLA in 63% weight-to-weight
NMP. It was provided in a single syringe and applied to
qualifying sites as previously described for DH.
Quadrants treated with DH and VC were covered
with a periodontal dressing.‡‡‡‡ Subjects in these treat-
ment groups returned at day 7 for removal of the dress-
ing and test material (subsequent studies have shown
that removal of DH is unnecessary; unpublished data).
DH and VC were applied to each qualifying pocket in 2
treated quadrants in subjects randomized to that
†††† Atridox, Block Drug Corporation, Inc., Jersey City, NJ.
‡‡‡‡ Coe-Pak periodontal dressing, GC America, Inc., Chicago, IL.
respective treatment group at baseline and month 4
visits. Subjects in these 2 treatment groups were
instructed not to perform oral hygiene on the treated
quadrants for 7 days following treatment. Untreated
quadrants received no treatment other than oral
hygiene during the study.
Subjects randomized to the oral hygiene group (OH)
were instructed in the Bass brushing technique, as well
as the proper use of dental floss. They were instructed
to brush and floss 2 times a day. Oral hygiene compli-
ance was queried at each subsequent visit, and further
instruction provided as necessary. Subjects receiving
DH, VC, or SRP treatments also received oral hygiene
instructions identical to those received by the subjects
in the OH group.
Subjects randomized to receive SRP received a sin-
gle episode of SRP in the 2 treated quadrants at base-
line, repeated at month 4. Therapists were instructed to
continue the SRP until treated root surfaces felt hard
and smooth to a dental explorer. Subjects were given
local anesthesia on request. No time restraints were
placed on the SRP therapist; instead, treatment pro-
ceeded until the therapist was entirely satisfied with the
endpoint. SRP therapists were either periodontists or
dental hygienists chosen by the principal investigator at
each study center. The untreated quadrants did not
receive mechanical instrumentation during the course
of the study. Subjects were instructed to begin oral
hygiene in the treated quadrants the day following SRP.
Treatment Assignment and Blinding
All subjects were randomized to treatment groups
according to a computer-generated random code.
These were single-blind studies, in that the examiners
at each center were blinded to treatment. A double-
blind design was not possible because of the dissimilar
treatments between various treatment groups.
EVALUATIONS
A schedule of the evaluation timepoints and data col-
lection at each timepoint is outlined in Figure 1.
Measurements of probing depth, bleeding on probing,
clinical attachment level, and plaque index16-18 were
made at these timepoints. Probing measurements were
made at 6 location points on all teeth in the dentition
using a periodontal probe§§§§ graduated in 1 mm incre-
ments with readings made to the nearest millimeter.
Four or 5 sites in each of the quadrants that qualified
for the study were selected for attachment level mea-
surements using the cemento-enamel junction (CEJ),
or other nearby landmark. Duplicate attachment level
measurements were made at each attachment level site
during each exam with approximately 20 minutes
between the recordings. The average of these 2 record-
ings was used as the attachment level measurement for
that site. Concomitant medications and safety evalua-
tions were recorded at each visit. Any suspected
adverse events or allergic responses were evaluated
carefully by the investigator. Further details concerning
these evaluation appointments have been published
previously.13
Pre-Study Training
Details of the elements of the pre-study calibration and
center training program have been previously
described.13 In these studies, all examiners were cali-
brated to one gold standard examiner (author CQH).
Calibration continued until examiners reached levels
previously described.13 Study teams not involved in a
previous multi-center study12 carried out a training
study in which 4 to 10 subjects were entered, treated
with DH, and followed for 30 days. This was done under
a separate protocol, and data from these subjects are
not included in this report.
Statistical Methods
The studies were powered to show a 0.35 mm differ-
ence between treatment groups as significant. This
required a sample size of approximately 100 subjects
per treatment group at 80% power. The primary effi-
cacy endpoints were mean change in attachment level
and probing depth. Means were calculated using the
sum of the treated site measurements for a subject
divided by the number of treated sites. For all parame-
ters, the subject mean was the basis of the statistical
analysis, not the sites alone.19,20 Efficacy results for
qualifying treated sites for attachment level and probing
depth were analyzed statistically by analysis of variance
(ANOVA) on differences from baseline values between
groups. The null hypothesis was that there were no
treatment group differences. All statistical tests were
conducted at a significance level of P ≤0.05. All tests
were 2-tailed.
Study procedures involving criteria for study monitor-
ing, data management and exclusion of subjects, tooth
sites, or investigators/centers have all been described
previously13 and will not be reviewed in this report.
RESULTS
The efficacy parameters evaluated were mean change
in attachment level and mean change in probing depth.
ANOVA analyses are presented for data combined from
all centers in each study for each parameter and treat-
ment group. The number of subjects per group avail-
able for analysis varied at each analysis timepoint
based on a blinded determination of whether they were
efficacy-evaluable at that particular study timepoint.
Plaque score changes are presented as well, as a mea-
surement of compliance.
Clinical Attachment Level Gain (ALG) – Mean Data
Study 1. Mean ALG for all subjects is represented in
Table 1. All treatment groups showed improvement
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from baseline in ALG. The majority of the gain occurred
at month 1 and was generally sustained through
month 4. Re-treatment at month 4 resulted in a small
incremental gain in the DH and SRP groups which was
maintained through month 9. No additional improve-
ment was observed in the VC and OH groups. The VC
group lost most of the initial gain as the study
approached month 9. Results in the DH group were sta-
tistically significant (P ≤0.05) when compared with the
VC and OH groups after month 1. DH and SRP results
were nearly identical over time. The mean ALG at
month 9 was 0.8 mm in the DH group and 0.7 mm in
the SRP group.
Study 2. Mean ALG in Study 2 followed a similar
pattern to Study 1. Again, the majority of the change
occurred by month 1 with additional improvement at
month 4 in the DH and SRP groups. Results in the DH
group were statistically significant (P ≤0.05) when com-
pared with VC and OH after month 1. DH and SRP
results were nearly identical over time with mean ALG
of 0.8 mm and 0.9 mm for the DH and SRP groups,
respectively, at month 9. In this study, the initial VC
benefit was maintained throughout the study. The oral
hygiene effect was consistently somewhat stronger than
that observed in Study 1. 
Probing Depth Reduction (PD) – Mean Data
Study 1. Mean PD reduction for all subjects is pre-
sented in Table 2. As with ALG, most of the improve-
ment was noted at month 1, with incremental benefits
following the month 4 re-treatment in the DH and SRP
groups. No additional benefit was observed in the other
Figure 1.
Schematic outline of study procedures.
Treatment Day
Day 7
Screen Baseline Interim Day Month Month Interim Post- Month
Visit 7 1,2 4 Visit Reapp 5,6,8,9
Informed consent X
Admission criteria X X
Pregnancy test X X X
Demographics X
Medical history X
Blood pressure and pulse rate X X X
Clinical photographs X X X X X X X X
Periodontal history X
Plaque index X X X X
Periodontal examination X X X X X
Administer treatments X X
Test article retention form X X X X
Oral hygiene instruction X X X X
Treatment accountability X X
Replace periodontal dressing (as needed) X X
Removal of periodontal dressing X X
Removal of test articles X X
Adverse events/illnesses X X X X X X X X
Concomitant medications X X X X X X X X X
Provide/check dental supplies X X X X
Clinical visit X X X X X X X X X
treatment groups. As with ALG, DH results were gener-
ally statistically superior (P ≤0.05) to VC and OH groups
beginning at month 1. Again, results in the DH and SRP
groups were nearly identical over time, although the DH
group was statistically superior (P ≤0.05) at month 9
(DH reduction 1.1 mm; SRP reduction 0.9 mm). Unlike
ALG, the VC group generally showed somewhat more
PD reduction than the OH group.
Study 2. Mean PD reduction in Study 2 was similar
to that in Study 1, with the DH group results superior
(P ≤0.05) to VC and OH beginning at month 1. Again
there was incremental benefit to the re-treatment at
month 4 in the DH and SRP groups. Results between
these groups were nearly identical (1.3 mm reduction
in both groups at month 9), as were results between
the VC and OH groups. As with ALG, the OH
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Table 1.
Gain in Attachment Level (mm)
Baseline Month 1 Month 2 Month 4 Month 5 Month 6 Month 8 Month 9
Study 1
DH
N 95 79 75 75 75 72 73 80
Mean (s.e.) 6.1 (0.2) 0.6 (0.1) 0.7 (0.1) 0.6 (0.1) 0.7 (0.1) 0.8 (0.1) 0.8 (0.1) 0.8 (0.1)
VC
N 94 85 78 82 76 79 78 82
Mean (s.e.) 6.1 (0.2) 0.4 (0.1) 0.4 (0.1) 0.3 (0.1) 0.3 (0.1) 0.1 (0.1) 0.1 (0.1) 0.1 (0.1)
OH
N 95 86 81 78 74 77 78 83
Mean (s.e.) 6.2 (0.2) 0.5 (0.1) 0.3 (0.1) 0.4 (0.1) 0.3 (0.1) 0.3 (0.1) 0.4 (0.1) 0.3 (0.1)
SRP
N 99 80 88 91 80 80 86 84
Mean (s.e.) 5.8 (0.2) 0.6 (0.1) 0.6 (0.1) 0.6 (0.1) 0.6 (0.1) 0.7 (0.1) 0.7 (0.1) 0.7 (0.1)
P value
DH vs.VC 0.062 0.001 0.028 0.008 <0.001 <0.001 <0.001
DH vs. OH 0.206 0.002 0.051 0.015 0.002 0.005 0.001
DH vs. SRP 0.615 0.175 0.680 0.569 0.510 0.728 0.294
Study 2
DH
N 96 86 84 88 79 80 84 85
Mean (s.e.) 5.6 (0.2) 0.6 (0.1) 0.6 (0.1) 0.7 (0.1) 0.8 (0.1) 0.8 (0.1) 0.9 (0.1) 0.8 (0.1)
VC
N 96 89 87 81 81 81 79 83
Mean (s.e.) 5.9 (0.2) 0.4 (0.1) 0.3 (0.1) 0.4 (0.1) 0.4 (0.1) 0.4 (0.1) 0.4 (0.1) 0.5 (0.1)
OH
N 94 85 86 89 89 88 85 89
Mean (s.e.) 6.0 (0.2) 0.4 (0.1) 0.4 (0.1) 0.5 (0.1) 0.5 (0.1) 0.5 (0.1) 0.5 (0.1) 0.5 (0.1)
SRP
N 103 90 91 90 86 90 97 98
Mean (s.e.) 5.7 (0.2) 0.6 (0.1) 0.6 (0.1) 0.6 (0.1) 0.7 (0.1) 0.7 (0.1) 0.8 (0.1) 0.9 (0.1)
P value
DH vs.VC 0.056 0.002 0.003 <0.001 0.003 <0.001 0.002
DH vs. OH 0.074 0.048 0.056 0.008 0.026 0.001 0.012
DH vs. SRP 0.662 0.847 0.783 0.226 0.313 0.603 0.665 
response was greater in Study 2 than in Study 1.
ALG and PD Reduction in Moderate Sites (Initial PD
5 to 6 mm)
Table 3 presents ALG for sites with moderate probing
depths at baseline. In Study 1, the DH treatment group
is statistically superior to VC and OH beginning at
month 1 and to SRP at months 6 through 9. There is lit-
tle additional benefit to the second treatment at month 4
in any of the treatment groups. At month 9, there is little
benefit observed in the VC and OH groups, and the ALG
of the DH group is double that of the SRP group
(0.6 mm versus 0.3 mm). In Study 2 there are no differ-
ences between the DH and SRP groups. Changes in
these groups are generally double the changes in the VC
and OH groups, with DH superior to VC beginning at
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Table 2.
Reduction in Probing Depth (mm)
Baseline Month 1 Month 2 Month 4 Month 5 Month 6 Month 8 Month 9
Study 1
DH
N 95 79 75 75 75 72 73 80
Mean (s.e.) 6.0 (<0.1) 0.9 (0.1) 0.9 (0.1) 0.9 (0.1) 1.1 (0.1) 1.1 (0.1) 1.1 (0.1) 1.1 (0.1)
VC
N 94 85 78 82 76 79 78 82
Mean (s.e.) 5.9 (<0.1) 0.7 (0.1) 0.7 (0.1) 0.8 (0.1) 0.8 (0.1) 0.8 (0.1) 0.7 (0.1) 0.8 (0.1)
OH
N 95 86 81 78 74 77 78 83
Mean (s.e.) 6.0 (<0.1) 0.6 (0.1) 0.6 (0.1) 0.6 (0.1) 0.5 (0.1) 0.5 (0.1) 0.5 (0.1) 0.5 (0.1)
SRP
N 99 80 88 91 80 80 86 84
Mean (s.e.) 5.9 (<0.1) 0.9 (0.1) 0.9 (0.1) 0.9 (0.1) 1.1 (0.1) 1.1 (0.1) 1.0 (0.1) 0.9 (0.1)
P value
DH vs. VC 0.010 0.018 0.096 0.004 0.015 <0.001 0.001
DH vs. OH 0.003 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
DH vs. SRP 0.954 0.877 0.624 0.994 0.900 0.337 0.050
Study 2
DH
N 96 86 84 88 79 80 84 85
Mean (s.e.) 5.9 (<0.1) 1.0 (0.1) 1.0 (0.1) 1.0 (0.1) 1.2 (0.1) 1.3 (0.1) 1.3 (0.1) 1.3 (0.1)
VC
N 96 89 87 81 81 81 79 83
Mean (s.e.) 6.0 (0.1) 0.6 (<0.1) 0.6 (0.1) 0.7 (0.1) 0.9 (0.1) 0.9 (0.1) 0.9 (0.1) 1.0 (0.1)
OH
N 94 85 86 89 89 88 85 89
Mean (s.e.) 5.9 (0.1) 0.6 (<0.1) 0.7 (0.1) 0.7 (0.1) 0.8 (0.1) 0.9 (0.1) 0.9 (0.1) 0.9 (0.1)
SRP
N 103 90 91 90 86 90 97 98
Mean (s.e.) 5.9 (<0.1) 1.0 (<0.1) 1.1 (0.1) 1.1 (0.1) 1.3 (0.1) 1.3 (0.1) 1.3 (0.1) 1.3 (0.1)
P value
DH vs. VC <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 0.001
DH vs. OH <0.001 <0.001 0.002 <0.001 <0.001 <0.001 <0.001
DH vs. SRP 0.322 0.279 0.642 0.505 0.988 0.865 0.765
month 2, and to OH beginning at month 3 throughout
the remainder of the study. At month 9, ALG for both
the DH and SRP groups was 0.7 mm.
Table 4 presents PD reductions for moderately deep
sites. In both studies, PD reduction is very similar
between the DH and SRP groups. Again, at all time-
points in both studies beginning at month 1, the DH
group is superior to the VC and OH groups. Month 9
reductions in the DH group were statistically superior to
the SRP group in Study 1 (0.9 mm versus 0.7 mm).
Both DH and SRP showed a 1.1 mm reduction at
month 9 in Study 2. In Study 1, PD reduction was
somewhat better in the VC group than the OH group. In
Study 2, results were very similar.
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Table 3.
Gain in Attachment Level (mm) for Initial Probing Depths of 5 to 6 mm
Baseline Month 1 Month 2 Month 4 Month 5 Month 6 Month 8 Month 9
Study 1
DH
N 93 77 74 73 73 70 71 78
Mean (s.e.) 5.3 (0.2) 0.5 (0.1) 0.6 (0.1) 0.5 (0.1) 0.6 (0.1) 0.7 (0.1) 0.6 (0.1) 0.6 (0.1)
VC
N 94 85 78 82 76 79 78 82
Mean (s.e.) 5.2 (0.2) 0.3 (0.1) 0.1 (0.1) 0.1 (0.1) 0.1 (0.1) 0.0 (0.1) 0.1 (0.1) 0.1 (0.1)
OH
N 94 85 80 77 73 76 77 82
Mean (s.e.) 5.5 (0.2) 0.3 (0.1) 0.1 (0.1) 0.1 (0.1) 0.1 (0.1) 0.2 (0.1) 0.2 (0.1) 0.1 (0.1)
SRP
N 98 79 87 91 79 80 85 84
Mean (s.e.) 5.0 (0.2) 0.3 (0.1) 0.3 (0.1) 0.3 (0.1) 0.3 (0.1) 0.3 (0.1) 0.3 (0.1) 0.3 (0.1)
P value
DH vs. VC 0.079 0.002 0.001 <0.001 <0.001 <0.001 <0.001
DH vs. OH 0.052 0.001 0.002 0.001 0.002 0.002 <0.001
DH vs. SRP 0.060 0.073 0.078 0.057 0.018 0.015 0.022
Study 2
DH
N 95 85 83 87 78 79 83 84
Mean (s.e.) 4.9 (0.2) 0.4 (0.1) 0.5 (0.1) 0.6 (0.1) 0.7 (0.1) 0.7 (0.1) 0.8 (0.1) 0.7 (0.1)
VC
N 94 87 85 80 80 80 78 82
Mean (s.e.) 5.1 (0.2) 0.3 (0.1) 0.2 (0.1) 0.3 (0.1) 0.3 (0.1) 0.3 (0.1) 0.3 (0.1) 0.3 (0.1)
OH
N 93 84 85 88 88 87 84 88
Mean (s.e.) 5.4 (0.2) 0.3 (0.1) 0.3 (0.1) 0.3 (0.1) 0.4 (0.1) 0.4 (0.1) 0.4 (0.1) 0.4 (0.1)
SRP
N 103 90 91 90 86 90 97 98
Mean (s.e.) 5.1 (0.2) 0.4 (0.1) 0.5 (0.1) 0.6 (0.1) 0.6 (0.1) 0.6 (0.1) 0.7 (0.1) 0.7 (0.1)
P value
DH vs. VC 0.110 0.004 0.003 <0.001 0.002 <0.001 <0.001
DH vs. OH 0.140 0.095 0.014 0.036 0.018 0.004 0.003
DH vs. SRP 0.987 0.962 0.834 0.643 0.736 0.698 0.738
ALG and PD Reduction in Severe Sites (Initial PD
≥7 mm)
Table 5 presents ALG for sites initially ≥7 mm in depth.
In both studies, the DH treatment group is superior to
OH at most timepoints. The DH and SRP groups
demonstrate very similar changes throughout the study.
VC shows a smaller clinical response than the DH and
SRP groups, although the differences are generally not
significantly different. The magnitude of ALG in sites
≥7 mm is greater in all treatment groups in both studies
than that seen in the moderate sites, and it is somewhat
greater than the overall mean changes.
Table 6 presents PD reduction in deeper sites. As
with previous analysis in both Study 1 and Study 2, the
majority of the change occurred at month 1, with a
small incremental benefit after the second treatment at
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Table 4.
Reduction in Probing Depth (mm) for Initial Probing Depths of 5 to 6 mm
Baseline Month 1 Month 2 Month 4 Month 5 Month 6 Month 8 Month 9
Study 1
DH
N 95 79 75 75 75 72 73 80
Mean (s.e.) 5.3 (<0.1) 0.7 (0.1) 0.8 (0.1) 0.7 (0.1) 1.0 (0.1) 0.9 (0.1) 0.9 (0.1) 0.9 (0.1)
VC
N 94 85 78 82 76 79 78 82
Mean (s.e.) 5.3 (<0.1) 0.5 (0.1) 0.6 (0.1) 0.5 (0.1) 0.7 (0.1) 0.6 (0.1) 0.5 (0.1) 0.6 (0.1)
OH
N 95 86 81 78 74 77 78 83
Mean (s.e.) 5.3 (<0.1) 0.4 (0.1) 0.4 (0.1) 0.3 (0.1) 0.3 (0.1) 0.3 (0.1) 0.3 (0.1) 0.3 (0.1)
SRP
N 99 80 88 91 80 80 86 84
Mean (s.e.) 5.3 (<0.1) 0.7 (0.1) 0.7 (0.1) 0.7 (0.1) 0.9 (0.1) 0.9 (0.1) 0.8 (0.1) 0.7 (0.1)
P value
DH vs. VC 0.009 0.005 0.014 <0.001 <0.001 <0.001 <0.001
DH vs. OH <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
DH vs. SRP 0.625 0.518 0.604 0.508 0.624 0.358 0.018
Study 2
DH
N 96 86 84 88 79 80 84 85
Mean (s.e.) 5.3 (<0.1) 0.8 (<0.1) 0.8 (0.1) 0.9 (0.1) 1.1 (0.1) 1.1 (0.1) 1.2 (0.1) 1.1 (0.1)
VC
N 96 89 87 81 81 81 79 83
Mean (s.e.) 5.3 (<0.1) 0.5 (<0.1) 0.5 (0.1) 0.5 (0.1) 0.7 (0.1) 0.8 (0.1) 0.7 (0.1) 0.7 (0.1)
OH
N 94 85 86 89 89 88 85 89
Mean (s.e.) 5.3 (<0.1) 0.4 (<0.1) 0.5 (0.1) 0.6 (0.1) 0.7 (0.1) 0.7 (0.1) 0.7 (0.1) 0.7 (0.1)
SRP
N 103 90 91 90 86 90 97 98
Mean (s.e.) 5.3 (<0.1) 0.9 (<0.1) 0.9 (0.1) 1.0 (0.1) 1.1 (0.1) 1.1 (0.1) 1.1 (0.1) 1.1 (0.1)
P value
DH vs. VC <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
DH vs. OH <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
DH vs. SRP 0.155 0.359 0.567 0.985 0.836 0.687 0.954
month 4 in the DH and SRP groups. DH treatment was
statistically superior (P ≤0.05) to OH at all timepoints
beginning at month 1 in both studies. DH was superior
to VC at all timepoints in Study 2 and at most time-
points in Study 1. DH and SRP showed nearly identical
responses throughout both studies. The overall magni-
tude of the clinical change in all treatment groups was
greater in Study 2 compared to Study 1. Changes in
the VC group were generally greater than the OH group
in both studies.
Frequency of Change (Frequency Distribution) ALG
and PD Reductions
Table 7 presents the frequency of ALG change for sites
evaluated for ALG in both Study 1 and Study 2. Sites
that exhibited a ≥2 mm ALG are nearly identical when
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Table 5.
Gain in Attachment Level (mm) for Initial Probing Depths of ≥7 mm
Baseline Month 1 Month 2 Month 4 Month 5 Month 6 Month 8 Month 9
Study 1
DH
N 92 76 73 73 72 70 71 78
Mean (s.e.) 7.3 (0.2) 0.9 (0.1) 0.8 (0.1) 0.8 (0.1) 0.7 (0.1) 0.9 (0.1) 0.8 (0.1) 0.9 (0.1)
VC
N 94 85 78 80 74 75 76 80
Mean (s.e.) 7.3 (0.2) 0.7 (0.1) 0.7 (0.1) 0.8 (0.1) 0.6 (0.1) 0.8 (0.1) 0.6 (0.1) 0.6 (0.1)
OH
N 94 83 79 77 72 76 76 81
Mean (s.e.) 7.4 (0.3) 0.6 (0.1) 0.5 (0.1) 0.4 (0.1) 0.4 (0.1) 0.5 (0.1) 0.5 (0.1) 0.4 (0.1)
SRP
N 98 80 87 91 79 79 84 82
Mean (s.e.) 7.0 (0.2) 0.9 (0.1) 0.9 (0.1) 0.9 (0.1) 1.0 (0.1) 1.0 (0.1) 1.2 (0.1) 1.0 (0.1)
P value
DH vs. VC 0.156 0.296 0.874 0.423 0.645 0.287 0.097
DH vs. OH 0.026 0.063 0.037 0.060 0.050 0.071 0.015
DH vs. SRP 0.958 0.625 0.394 0.173 0.450 0.065 0.451
Study 2
DH
N 90 82 81 81 73 73 76 77
Mean (s.e.) 7.2 (0.3) 0.8 (0.1) 0.8 (0.1) 0.9 (0.1) 1.1 (0.1) 1.2 (0.1) 1.3 (0.1) 1.1 (0.1)
VC
N 89 82 79 73 75 76 73 76
Mean (s.e.) 7.3 (0.3) 0.8 (0.1) 0.6 (0.1) 0.7 (0.1) 0.8 (0.1) 0.9 (0.1) 0.9 (0.1) 0.9 (0.1)
OH
N 90 82 83 87 86 86 82 86
Mean (s.e.) 7.1 (0.3) 0.7 (0.1) 0.6 (0.1) 0.8 (0.1) 0.8 (0.1) 0.8 (0.1) 0.7 (0.1) 0.8 (0.1)
SRP
N 96 83 85 85 80 83 91 91
Mean (s.e.) 7.0 (0.2) 0.7 (0.1) 0.8 (0.1) 0.8 (0.1) 0.9 (0.1) 0.9 (0.1) 1.1 (0.1) 1.1 (0.1)
P value
DH vs. VC 0.805 0.090 0.209 0.089 0.150 0.054 0.522
DH vs. OH 0.433 0.095 0.483 0.035 0.032 0.005 0.183
DH vs. SRP 0.465 0.977 0.626 0.125 0.124 0.272 0.868
DH and SRP groups are compared in both studies. The
VC group generally shows a frequency of 6% to 10%
less than these groups, and the OH group shows a fre-
quency somewhat less than the VC group. In Study 1 at
month 9, 29% of treated sites in the DH group and 27%
of treated sites in the SRP group showed a ≥2 mm ALG.
In Study 2, 31% of treated sites in the DH group and
34% in the SRP group showed a ≥2 mm ALG.
Table 8 shows the frequency of PD change for all
treated sites. When evaluating sites that showed ≥2 mm
PD reduction at month 9, the DH and SRP groups showed
similar responses, with 32% of the DH sites and 31% of the
SRP sites showing this change in Study 1, and 41% and
43% in Study 2, respectively. The VC group showed a 10%
to 15% less change of this magnitude in the 2 studies; the
OH group showed a 15% to 20% less change.
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Table 6.
Reduction in Probing Depth (mm) for Initial Probing Depths of ≥7 mm
Baseline Month 1 Month 2 Month 4 Month 5 Month 6 Month 8 Month 9
Study 1
DH
N 95 79 75 74 74 72 73 80
Mean (s.e.) 7.5 (0.1) 1.3 (0.1) 1.3 (0.1) 1.3 (0.1) 1.5 (0.1) 1.5 (0.1) 1.5 (0.1) 1.6 (0.1)
VC
N 94 85 78 80 74 75 76 80
Mean (s.e.) 7.5 (0.1) 1.0 (0.1) 1.0 (0.1) 1.1 (0.1) 1.2 (0.1) 1.2 (0.1) 1.1 (0.1) 1.1 (0.1)
OH
N 95 84 79 77 72 76 76 81
Mean (s.e.) 7.6 (0.1) 0.9 (0.1) 0.9 (0.1) 0.8 (0.1) 1.0 (0.1) 0.8 (0.1) 1.0 (0.1) 0.9 (0.1)
SRP
N 99 80 88 91 80 80 85 83
Mean (s.e.) 7.6 (0.1) 1.5 (0.1) 1.4 (0.1) 1.5 (0.1) 1.6 (0.1) 1.7 (0.1) 1.6 (0.1) 1.5 (0.1)
P value
DH vs. VC 0.016 0.068 0.126 0.014 0.058 0.014 0.002
DH vs. OH 0.001 0.008 0.002 <0.001 <0.001 0.001 <0.001
DH vs. SRP 0.341 0.244 0.332 0.293 0.260 0.783 0.569
Study 2
DH
N 96 86 84 87 77 78 82 83
Mean (s.e.) 7.6 (0.1) 1.4 (0.1) 1.5 (0.1) 1.4 (0.1) 1.9 (0.1) 1.8 (0.1) 1.9 (0.1) 1.9 (0.1)
VC
N 94 87 84 78 79 79 78 81
Mean (s.e.) 7.6 (0.1) 1.0 (0.1) 0.9 (0.1) 1.1 (0.1) 1.3 (0.1) 1.4 (0.1) 1.4 (0.1) 1.6 (0.1)
OH
N 93 84 85 88 88 87 84 88
Mean (s.e.) 7.5 (0.1) 1.0 (0.1) 1.1 (0.1) 1.1 (0.1) 1.3 (0.1) 1.3 (0.1) 1.3 (0.1) 1.3 (0.1)
SRP
N 103 90 91 89 85 89 96 97
Mean (s.e.) 7.5 (0.1) 1.4 (0.1) 1.6 (0.1) 1.5 (0.1) 1.8 (0.1) 1.7 (0.1) 1.8 (0.1) 1.8 (0.1)
P value
DH vs. VC 0.007 <0.001 0.051 <0.001 0.007 0.001 0.050
DH vs. OH 0.005 0.007 0.040 <0.001 <0.001 <0.001 <0.001
DH vs. SRP 0.809 0.327 0.831 0.762 0.512 0.558 0.489
Plaque Scores
Baseline plaque scores18 for each treatment group in
Study 1 were: DH=1.0; VC=1.0; OH=1.1; SRP=1.1.
Average reductions for the treatment groups over the
course of Study 1 were: DH=0.13; VC=0.07; OH=0.16;
SRP=0.20. In Study 2, baseline scores were: DH=1.0;
VC=1.0; OH=1.1; SRP=1.1. Average reductions for the
treatment groups during the study were: DH=0.16;
VC=0.07; OH=0.27; SRP=0.14.
Safety
In Study 1, there were 54 (DH=17; VC=24; OH=1;
SRP=12) treatment-related adverse events reported
(defined as probably or possibly related to treatment).
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Table 7.
Frequency of Attachment Level Change by Gain, No Change, and Loss
DH VC OH SRP
Month 4 6 9 4 6 9 4 6 9 4 6 9
Study 1
Gain
≥1 mm Sites 369 355 402 357 350 358 303 315 304 452 408 420
% 57 59 60 53 55 54 48 50 47 59 62 60
≥2 mm Sites 173 162 190 152 153 145 110 130 101 205 187 189
% 27 27 29 23 24 22 17 21 16 27 28 27
≥3 mm Sites 69 64 73 46 45 43 27 39 30 59 57 56
% 11 11 11 7 7 7 4 6 5 8 9 8
No Change
0 mm Sites 116 116 126 137 104 97 132 125 135 141 96 115
% 18 19 19 20 16 15 21 20 21 18 14 17
Loss
≥1 mm Sites 161 129 137 176 183 202 194 193 211 175 159 160
% 25 22 21 26 29 31 31 30 32 23 24 23
≥2 mm Sites 32 40 37 56 61 65 48 61 71 53 43 46
% 5 7 6 8 10 10 8 10 11 7 6 7
≥3 mm Sites 9 15 10 19 23 24 15 16 19 9 5 10
% 1 3 2 3 4 4 2 3 3 1 1 1
Total Sites 646 600 665 670 637 657 629 633 650 768 663 695
Study 2
Gain
≥1 mm Sites 460 451 465 349 371 375 390 415 423 457 502 549
% 61 67 66 52 56 56 52 56 57 61 65 67
≥2 mm Sites 198 208 222 122 155 161 160 171 154 199 242 278
% 26 31 31 18 23 24 21 23 21 27 31 34
≥3 mm Sites 71 62 75 25 49 38 56 45 52 58 68 92
% 9 9 11 4 7 6 7 6 7 8 9 11
No Change
0 mm Sites 146 110 131 142 120 129 179 153 155 143 111 123
% 19 16 19 21 18 19 24 21 21 19 14 15
Loss
≥1 mm Sites 150 109 112 178 175 169 178 168 158 149 157 149
% 20 16 16 27 26 25 24 23 21 20 20 18
≥2 mm Sites 28 33 29 47 43 44 47 36 44 47 38 37
% 4 5 4 7 6 7 6 5 6 6 5 5
≥3 mm Sites 3 6 8 13 12 10 12 8 10 14 8 9
% <1 1 1 2 2 1 2 1 1 2 1 1
Total Sites 756 670 708 669 666 673 747 736 7.6 749 770 821
A large majority of these events were related to mild or
moderate gingival soreness following treatment. Two
subjects withdrew from the study due to treatment-
related adverse events. Both were in the VC treatment
group. One subject withdrew because of gingival sore-
ness resulting from VC placement. The second subject
experienced a mild erythematous reaction and a burn-
ing sensation at the site of placement. This reflects an
incidence of this event of <1% of the subjects treated
with VC. 
Treated sites were exited when an attachment loss
≥2 mm from baseline was detected. Sixty-five subjects
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Table 8.
Frequency of Probing Depth Change by Reduction, No Change, and Gain
DH VC OH SRP
Month 4 6 9 4 6 9 4 6 9 4 6 9
Study 1
Reduction
≥1 mm Sites 784 798 902 665 668 676 621 643 624 1046 998 951
% 60 64 66 52 54 53 46 47 46 63 71 66
≥2 mm Sites 346 385 441 233 264 282 199 201 203 468 510 447
% 27 31 32 18 21 22 15 15 15 28 37 31
≥3 mm Sites 109 140 143 57 70 79 50 48 59 141 138 125
% 8 11 10 4 6 6 4 4 4 8 10 9
No Change
0 mm Sites 383 332 374 480 407 426 510 509 512 473 308 345
% 29 27 27 37 33 34 38 37 38 28 22 24
Gain
≥1 mm Sites 133 108 94 144 169 168 221 207 223 141 90 144
% 10 9 7 11 14 13 16 15 16 8 6 10
≥2 mm Sites 23 18 17 28 27 24 48 56 53 33 22 28
% 2 1 1 2 2 2 4 4 4 2 2 2
≥3 mm Sites 5 3 1 5 6 4 19 21 20 13 10 10
% <1 <1 <1 <1 <1 <1 1 2 1 1 1 1
Total Sites 1300 1238 1370 1289 1244 1270 1352 1359 1359 1660 1396 1440
Study 2
Reduction
≥1 mm Sites 1024 1045 1078 673 859 838 756 833 847 1058 1187 1230
% 65 75 72 51 62 59 53 59 60 69 74 73
≥2 mm Sites 480 568 611 232 375 387 285 329 328 559 693 720
% 30 41 41 18 27 27 20 23 23 36 43 43
≥3 mm Sites 133 198 218 61 107 115 78 84 85 214 276 294
% 8 14 14 5 8 8 5 6 6 14 17 17
No Change
0 mm Sites 439 267 325 513 417 461 508 460 440 371 329 356
% 28 19 22 39 30 33 36 33 31 24 21 21
Gain
≥1 mm Sites 114 74 98 139 99 110 163 118 123 103 85 99
% 7 5 7 10 7 8 11 8 9 7 5 6
≥2 mm Sites 22 23 20 21 21 16 27 22 27 18 17 20
% 1 2 1 2 2 1 2 2 2 1 1 1
≥3 mm Sites 7 13 4 5 6 2 8 6 9 6 3 5
% <1 1 <1 <1 <1 <1 1 <1 1 <1 <1 <1
Total Sites 1577 1386 1501 1325 1375 1409 1427 1411 1410 1532 1601 1685
(16%) had treated teeth exited from analysis. The per-
centage of subjects with exited treated sites relative to
treatment group was 13% for DH, 14% for VC, 19% for
OH, and 17% for SRP.
In Study 2, there were 80 (DH=21; VC=27; OH=9;
SRP=23) treatment-related adverse events reported.
Again, a large majority of these events were related to
mild or moderate gingival soreness following treatment.
One subject withdrew from the study due to a treat-
ment-related adverse event. This subject was in the VC
treatment group and apparently experienced an exac-
erbation of an undiagnosed periodontic/endodontic
lesion at the time of VC placement.
Fifty-four subjects (13%) had treated teeth exited for
the previously described reason. The percentage of
subjects with exited treated sites relative to treatment
group was 15% for DH, 16% for VC, 13% for OH, and
8% for SRP.
No subjects in either study experienced an outbreak
of oral candidiasis.
DISCUSSION
Both multi-center trials show clinically similar results for
PD reduction and ALG when the DH treatment is com-
pared to SRP. The DH treatment groups did not receive
mechanical treatment other than OH throughout the
study. The SRP arm was not controlled for time of
instrumentation or use of local anesthesia as has been
done in previous trials.21,22 Therapists used local anes-
thesia at the patients’ request and performed SRP until
the root surfaces were hard and smooth to an explorer.
These data demonstrate that in these large subject pop-
ulations, 2 applications of DH 4 months apart were as
effective as repeated SRP treatments 4 months apart in
reducing the clinical signs of periodontitis. Frequency
distributions demonstrated the same pattern of similar
effectiveness. Changes associated with the SRP groups
are similar to previously described changes following
definitive SRP of pockets with this initial depth.3,23 It
should be noted that the duration of this study was 9
months and that longer observation periods may have
indicated the need for mechanical debridement of the
pockets.
Results of both trials demonstrate superiority for the
DH treatment group compared to OH and VC treatment
groups. This is true for overall mean PD reduction and
ALG and is apparent when sites are grouped according
to initial probing depth in moderate (5 to 6 mm) and
deep (≥7 mm) site data sets. Frequency distributions
also demonstrate the same advantage for the DH
group. The activity of the VC treatment group was gen-
erally similar to the OH group with some additional
benefit particularly in deeper sites. This was most
noticeable when ALG for sites ≥7mm was compared.
This supports previous suggestions that this vehicle has
some inherent activity on its own.12,24 
Most of the clinical changes resulted from baseline
treatment and occurred over the first few months. There
were small incremental changes following the repeated
treatment at month 4, especially in the DH and SRP
treatment groups, although these improvements were
much less than the changes following the initial treat-
ment. Other studies have assessed subgingival antimi-
crobial treatment without concomitant SRP as well as
adjunctive to SRP.10 Results of this trial compare favor-
ably with these trials.
The safety profile in the DH treatment group showed
a very low incidence of treatment-related adverse
events. The most common event was a mild gingival
soreness after placement. This usually resolved within a
day or two. One subject in Study 1 experienced symp-
toms suggesting a localized allergic response associ-
ated with placement of the VC. This resolved shortly
after removal and represents an overall incidence of
<1% of treated subjects from the 2 studies. No subjects
from either study experienced difficulties with oral can-
didiasis. Use of the DH product does not appear to
place subjects at additional risk beyond that experi-
enced with traditional periodontal therapy.
To be effective in vivo, a pharmacologic agent must
meet 3 described criteria: 1) reach the site of action;
2) be maintained there in a sufficient concentration;
and 3) be maintained long enough for the intended
effect to occur.25 In treating periodontitis with local anti-
infective agents, the delivery system for the active
agent is particularly important because of the turnover
of gingival fluid in the periodontal pocket, and its ability
to flush these agents from the pocket.26 Delivery sys-
tems have been categorized as sustained or controlled
devices based on how long the delivered agent is avail-
able. Sustained devices generally provide delivery for
less than 24 hours. Controlled delivery devices should
provide delivery for more than one day.27,28
Pharmacokinetic evaluation of doxycycline delivery to
treated sites indicates that this delivery system func-
tions as a controlled delivery device with minimum
inhibitory concentrations (MIC90) of doxycycline well
above the MIC90 for suspected periodontal pathogens
for 7 to 10 days.29 The advantages of controlled deliv-
ery devices are described as: 1) better subject compli-
ance; 2) enhanced or improved pharmacokinetic
response; 3) a greater advantage in positioning the
active agent in proximity to the disease; and 4) delivery
of a lower total dose of drug at a more controlled con-
centration.25 Prolonged delivery at high concentrations
may be particularly important in periodontitis-involved
sites because subgingival plaque tends to organize as a
biofilm. Antimicrobial action on bacteria organized in a
biofilm may require concentrations of active agents that
are several times higher than those effective against
bacteria grown on agar plates.30,31
Subsequent research reports will present analyses
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for smokers versus non-smokers, response of sub-
jects related to periodontal treatment history, and
response of furcation and non-furcation sites.
In summary, data from these 2 multi-center trials
demonstrate: 1) DH treatment and SRP treatment result
in clinically equivalent results in both ALG and PD
reduction in both studies; 2) DH treatment is clearly
superior to OH and VC treatments in terms of ALG and
PD reduction in both studies; and 3) DH treatment pre-
sents with a very benign safety profile. Subjects are not
at any additional risk following this treatment compared
to standard periodontal therapies.
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